You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

OSIM

Cancer Type: Lung, Non-Small Cell      Intent: Palliative
Regimen Category: Evidence-Informed
Funding:
Exceptional Access Program
    Osimertinib - Second-line monotherapy of patients with locally advanced or metastatic EGFR T790M mutation-positive non-small cell lung cancer, according to specific criteria

You might also be interested in